The first melanoma patient treated with Neooncovac is feeling well and has developed the required immune response
The first patient to receive Russia’s personalized melanoma vaccine is feeling well and has developed the immune response needed to fight the disease, said Aleksandr Ginzburg, the scientific director of the Gamaleya Research Institute, which helped develop the treatment.
Last year, the Russian Health Ministry approved two domestically developed personalized cancer treatments: an mRNA-based vaccine for advanced melanoma named Neooncovac and a peptide medicine targeting colorectal cancer dubbed Oncopept.
Neooncovac was administered to its first patient in April. The recipient is a 60-year-old man with stage-three melanoma and metastases, who is being treated at the Herzen Moscow Oncology Research Institute.
According to Ginzburg, the patient is “feeling completely normal” and continuing treatment. Tests have shown “very positive” immunological responses, with the body producing the active compounds needed for the immune system to fight the tumor and its metastases, he told RIA Novosti on Thursday.
The patient is expected to receive two further doses of the medicine. His immune response will continue to be monitored throughout the treatment, Ginzburg said.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: rt.com
